Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have entered into a strategic agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for cancer patients in Japan, South Korea and Taiwan.
Under the deal, both the firms will jointly develop and commercialize Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumor types. Development costs and commercial profits will be shared equally when Opdivo is used in combination with any BMS compounds.
The deal has three additional early-stage clinical immuno-oncology assets from BMS, which include lirilumab, an antibody that blocks the KIR receptor on natural killer cells, urelumab, an agonist of the CD137 co-stimulatory receptor, and BMS-986016, a LAG3 immune checkpoint inhibitor.
Both the firms will jointly pursue development of monotherapy and combination regimens, with Opdivo as the foundational therapy in Japan, South Korea and Taiwan, and leverage global clinical trials by including patients from the three countries.
Read the report here: http://bit.ly/1pLpT1n